Regeneron to collaborate on gene editing therapies with Doudna-founded
Mammoth
Send a link to a friend
 [April 25, 2024]
(Reuters) - Regeneron Pharmaceuticals and Mammoth Biosciences
will collaborate to research, develop and commercialize gene editing
therapies for multiple diseases, the companies said on Thursday.
Mammoth's CRISPR-based gene editing platform and Regeneron's delivery
technologies will be used to create disease-modifying medicines that can
be delivered to tissues beyond the liver.
CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder
Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts
of genes that can then be disabled or replaced with new strands of
normal DNA.
In 2023, the U.S. FDA approved five gene therapies, including a sickle
cell disease treatment from Vertex Pharmaceuticals and CRISPR
Therapeutics that uses the latter's gene editing technology.
Regeneron joins drugmakers Bayer and Vertex Pharmaceuticals in striking
partnership deals with Mammoth for development of gene therapies.
Mammoth, which was founded by Doudna, will receive $100 million in total
upfront payment and equity investment from Regeneron and could receive
up to $370 million per therapy in development, regulatory and commercial
milestone payments.
[to top of second column]
|
The Regeneron Pharmaceuticals company logo is seen on a building at
the company's Westchester campus in Tarrytown, New York, U.S.
September 17, 2020. Picture taken September 17, 2020.
REUTERS/Brendan McDermid/File Photo/File Photo/File Photo
 The parties will jointly select and
research for the therapies, and then Regeneron will lead development
and commercialization.
(Reporting by Christy Santhosh in Bengaluru; Editing by Krishna
Chandra Eluri)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
